Home
Resources
Publications
Involvement of Soluble Receptor Activator of Nuclear factor-κB Ligand (sRANKL) in Collagenase-Induced Murine Osteoarthritis and Human Osteoarthritis

Involvement of Soluble Receptor Activator of Nuclear factor-κB Ligand (sRANKL) in Collagenase-Induced Murine Osteoarthritis and Human Osteoarthritis

Petya Dimitrova, Antoaneta Toncheva, Valeriya Gyurkovska, Nina Ivanovska

Rheumatol Int. 2012 May;32(5):1317-25.

PMID: 21290130

Abstract:

Joint destruction and excessive bone formation are associated with high expression of soluble receptor activator of nuclear factor-κB ligand (sRANKL). This study was undertaken to investigate the role of sRANKL in collagenase-induced osteoarthritis (CIOA) in mice and in patients with osteoarthritis (OA). The initial phase of CIOA was associated with severe proteoglycan depletion, decreased collagen density, and up-regulation of bone morphogenetic protein (BMP)-2. At the late stage of CIOA, bone remodeling was related with increased BMP2 and RANKL expression in the joints, high sRANKL, and decreased number of activated neutrophils in synovium. CIOA mice showed elevated plasma level of sRANKL but low RANKL expression on blood neutrophils. The percentage of RANKL-positive blood neutrophils was higher in patients with OA than in healthy individuals. Our data indicate that increased local and systemic levels of soluble RANKL might be indicative for OA disorders in mouse and human.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
IAR4248882	sRANKL human			Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: